CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...

GlaxoSmithKline (GSK – Research Report ... being broadly in line with consensus but showing signs of weakness in the vaccine segment. This is attributed to disappointing performances from ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...

The lawsuit claims GlaxoSmithKline replaced Flovent with an identical generic version, hurting patients whose insurance wouldn't cover it and costing taxpayers money. Arizona Attorney General Kris ...

Pharmaceutical giant GlaxoSmithKline will buy the oncology biotech company ... Endpoints News notes that Zejula is one of several PARP inhibitors that have reached the market, after AstraZeneca gained ...

BURLINGAME, CA, UNITED STATES, January 15, 2025 /EINPresswire / -- Latest Report, titled“Herpes Simplex Virus (Hsv) Vaccines Market” Trends, Share, Size, Growth, Opportunity and Forecast 2025 ...

BURLINGAME, CA, UNITED STATES, January 9, 2025 /EINPresswire / -- This report on the Diabetic Neuropathy Market offers an comprehensive analysis of the current trends, Market size, and projections ...

London stocks nudged higher in early trade on Wednesday as investors mulled disappointing US tech results and continued to ...